ArticleMolecular biology reports2026
Cell line-specific antileukemic effects of imipramine: apoptosis, reactive oxygen species modulation and cytokine responses in human acute promyelocytic leukemia and chronic myelogenous leukemia cells.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveImipramine, a tricyclic antidepressant, has recently attracted interest due to its potential anticancer properties. This study investigated the antileukemic effects of imipramine in human leukemia cell lines, with particular emphasis on apoptosis induction, mitochondrial dysfunction, reactive oxygen species modulation, and cell cycle regulation.
methodsHuman acute promyelocytic (HL-60) and chronic myelogenous leukemia (K562) cells were treated with imipramine. Cell viability was assessed using the MTS assay. Apoptosis was analyzed by flow cytometry following FITC Annexin V and propidium iodide staining. Mitochondrial membrane potential, intracellular reactive oxygen species levels, gene expression (RT-qPCR), and protein expression (ELISA) were evaluated. Cell cycle distribution was determined by flow cytometric analysis. In addition, Semaphorin 3 A (SEMA3A) expression was examined.
resultsImipramine induced dose- and time-dependent cytotoxic effects in both HL-60 and K562 cells. Imipramine significantly increased apoptotic cell populations, accompanied by mitochondrial dysfunction. SEMA3A expression was downregulated in HL-60 cells but unchanged in K562 cells. RT-qPCR analysis indicated limited, cell line–specific transcriptional modulation, characterized by significant BAK upregulation and CASP3 downregulation in HL-60 cells, while only non-significant upward trends were observed for apoptosis-related transcripts in K562 cells. Cell cycle analysis demonstrated S-phase accumulation together with reduced progression into mitosis, suggesting cell cycle arrest.
conclusionImipramine exhibits pronounced antileukemic activity through mitochondrial-dependent apoptotic mechanisms. These findings support the potential repurposing of imipramine as an anticancer agent and warrant further investigation into its therapeutic applicability.
Indexed as
Identifiers
41848779What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.